The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Functional Selective Oxytocin-derived Agonists Discriminate between Individual G Protein Family Subtypes
Open accessAbstract
We used a bioluminescence resonance energy transfer biosensor to screen for functional selective ligands of the human oxytocin (OT) receptor. We demonstrated that OT promoted the direct engagement and activation of G(q) and all the G(i/o) subtypes at the OT receptor. Other peptidic analogues, chosen because of specific substitutions in key OT structural/functional residues, all showed biased activation of G protein subtypes. No ligand, except OT, activated G(oA) or G(oB), and, with only one exception, all of the peptides that activated G(q) also activated G(i2) and G(i3) but not G(i1), G(oA), or G(oB), indicating a strong bias toward these subunits. Two peptides (DNalOVT and atosiban) activated only G(i1) or G(i3), failed to recruit β-arrestins, and did not induce receptor internalization, providing the first clear examples of ligands differentiating individual G(i/o) family members. Both analogs inhibited cell proliferation, showing that a single G(i) subtype-mediated pathway is sufficient to prompt this physiological response. These analogs represent unique tools for examining the contribution of G(i/o) members in complex biological responses and open the way to the development of drugs with peculiar selectivity profiles. This is of particular relevance because OT has been shown to improve symptoms in neurodevelopmental and psychiatric disorders characterized by abnormal social behaviors, such as autism. Functional selective ligands, activating a specific G protein signaling pathway, may possess a higher efficacy and specificity on OT-based therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insel, T. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.03.005 · Cited by 1,044
Oakley, R. H., Laporte, S. A., Holt, J. A., Barak, L. S., & Caron, M. G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101450200 · Cited by 455 · cited 2×
“Upon OT activation, OTRs are phosphorylated by GRK2, bind -arrestin, and are endocytosed via clathrin-coated vesicles (33, 42, 43); after internalization, they recycle back to the plasma membrane via the Rab4/Rab5 short recycling pathway (22).”
BackgroundMANNING, M., STOEV, S., CHINI, B., DURROUX, T., MOUILLAC, B., & GUILLON, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00437-8 · Cited by 296
Self-citationThe Binding Site of Neuropeptide Vasopressin V1a Receptor
Mouillac, B., Chini, B., Balestre, M.-N., Elands, J., Trumpp-Kallmeyer, S., Hoflack, J., Hibert, M., Jard, S., & Barberis, C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25771 · Cited by 262
Self-citationTyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor
Chini, B., Mouillac, B., Ala, Y., Balestre, M. N., Trumpp‐Kallmeyer, S., Hoflack, J., Elands, J., Hibert, M., Manning, M., & Jard, S. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07211.x · Cited by 179
Self-citationThe oxytocin receptor antagonist atosiban inhibits cell growth via a “biased agonist” mechanism
Reversi, A., Rimoldi, V., Marrocco, T., Cassoni, P., Bussolati, G., Parenti, M., & Chini, B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409945200 · Cited by 139
Self-citationConti, F., Sertic, S., Reversi, A., & Chini, B. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90590.2008 · Cited by 113 · cited 3×
“6e, stimulation with OT led to the appearance of punctate fluorescence after only 3 min, which, after 30 min, had almost completely disappeared from the plasma membrane but continued accumulating in the perinuclear region, thus indicating complete agonist-induced receptor internalization as reported previously (22).”
BackgroundMethodResultSelf-citation
Cited by
The oxytocin receptor: from intracellular signaling to behavior
Jurek, B., & Neumann, I. D. (2018) · Physiological Reviews · doi:10.1152/physrev.00031.2017 · Cited by 999
G protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome
Olsen, R. H. J., DiBerto, J. F., English, J. G., Glaudin, A. M., Krumm, B. E., Slocum, S. T., Che, T., Gavin, A. C., McCorvy, J. D., Roth, B. L., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0535-8 · Cited by 544
Neuromodulation by Oxytocin and Vasopressin
Stoop, R. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.025 · Cited by 506
Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02303.x · Cited by 423
Self-citationEliava, M., Melchior, M., Knobloch-Bollmann, H. S., Wahis, J., da Silva Gouveia, M., Tang, Y., Ciobanu, A. C., Triana del Rio, R., Roth, L. C., Althammer, F., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.041 · Cited by 409
Self-citationAssembling the puzzle: pathways of oxytocin signaling in the brain
Grinevich, V., Knobloch-Bollmann, H. S., Eliava, M., Busnelli, M., & Chini, B. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.04.013 · Cited by 309
Biased Receptor Signaling in Drug Discovery
Kenakin, T. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.016790 · Cited by 294
Biased Oxytocinergic Modulation of Midbrain Dopamine Systems
Xiao, L., Priest, M. F., Nasenbeny, J., Lu, T., & Kozorovitskiy, Y. (2017) · Neuron · doi:10.1016/j.neuron.2017.06.003 · Cited by 292
“In the central nervous system, Oxt binds to a single G-proteincoupled receptor (GPCR) (OxtR) primarily coupled toGaq protein effectors, but, at higher concentrations, Oxt is able to recruit Gai subunits (Busnelli et al., 2012).”
Recent developments in biased agonism
Wisler, J. W., Xiao, K., Thomsen, A. R., & Lefkowitz, R. J. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.10.008 · Cited by 287
Advances in therapeutic peptides targeting G protein-coupled receptors
Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H., & Maguire, J. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0062-z · Cited by 275
Duque-Wilckens, N., Steinman, M. Q., Busnelli, M., Chini, B., Yokoyama, S., Pham, M., Laredo, S. A., Hao, R., Perkeybile, A. M., Minie, V. A., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.024 · Cited by 181
Self-citationThe action radius of oxytocin release in the mammalian CNS: from single vesicles to behavior
Chini, B., Verhage, M., & Grinevich, V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.005 · Cited by 141
Interplay between Oxytocin and Sensory Systems in the Orchestration of Socio-Emotional Behaviors
Grinevich, V., & Stoop, R. (2018) · Neuron · doi:10.1016/j.neuron.2018.07.016 · Cited by 139
Sex-dependent regulation of social reward by oxytocin: an inverted U hypothesis
Borland, J. M., Rilling, J. K., Frantz, K. J., & Albers, H. E. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0129-2 · Cited by 116
Physiology of invertebrate oxytocin and vasopressin neuropeptides
Gruber, C. W. (2014) · Experimental Physiology · doi:10.1113/expphysiol.2013.072561 · Cited by 110
Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors
Busnelli, M., Bulgheroni, E., Manning, M., Kleinau, G., & Chini, B. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.202994 · Cited by 102
Self-citationSteinman, M. Q., Duque-Wilckens, N., & Trainor, B. C. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.10.008 · Cited by 105
Stoop, R. (2014) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.09.012 · Cited by 84
Oxytocin and vasopressin: signalling, behavioural modulation and potential therapeutic effects
Rae, M., Lemos Duarte, M., Gomes, I., Camarini, R., & Devi, L. A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15481 · Cited by 72
Busnelli, M., Kleinau, G., Muttenthaler, M., Stoev, S., Manning, M., Bibic, L., Howell, L. A., McCormick, P. J., Di Lascio, S., Braida, D., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00564 · Cited by 67
Self-citationOxytocin as a Modulator of Synaptic Plasticity: Implications for Neurodevelopmental Disorders
Rajamani, K. T., Wagner, S., Grinevich, V., & Harony-Nicolas, H. (2018) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2018.00017 · Cited by 53
Oxytocin receptor behavioral effects and cell types in the bed nucleus of the stria terminalis
Luo, P. X., Zakharenkov, H. C., Torres, L. Y., Rios, R. A., Gegenhuber, B., Black, A. M., Xu, C. K., Minie, V. A., Tran, A. M., Tollkuhn, J., et al. (2022) · Hormones and Behavior · doi:10.1016/j.yhbeh.2022.105203 · Cited by 27
Heterodimer of A2A and oxytocin receptors regulating glutamate release in adult striatal astrocytes
Amato, S., Averna, M., Guidolin, D., Pedrazzi, M., Pelassa, S., Capraro, M., Passalacqua, M., Bozzo, M., Gatta, E., Anderlini, D., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042326 · Cited by 23
Oxytocin increases eye gaze in schizophrenia
Bradley, E. R., Seitz, A., Niles, A. N., Rankin, K. P., Mathalon, D. H., O'Donovan, A., & Woolley, J. D. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.07.039 · Cited by 22
Metadata
- Authors
- Busnelli, M., Saulière, A., Manning, M., Bouvier, M., Galés, C., & Chini, B.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 287
- Issue
- 6
- Pages
- 3617-3629
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2073260721
- Cited by
- 195
- References
- 7
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.